Palvella Therapeutics
Price & Volume
Stats
See moreOpen | $58.38 |
Previous Close | $58.71 |
Day Range | $56.67-$59.05 |
52W Range | $11.17-$63.12 |
Market Cap | $219.3M |
Shares Short | 731,905 |
Financials
See moreRevenue (12 Mos) | $0 |
Revenue Growth (YoY) | 0% |
Gross Profit (12 Mos) | $0 |
Diluted EPS | $1.97 |
News
See moreYahoo Finance • 6 days ago
Palvella Therapeutics Announces Scientific Publication in Lymphatic Research and Biology Highlighting Recent Advances in the Pathogenesis of Venous Malformations and the Real-World Use of Rapamycin as an Emerging Targeted Therapy
Yahoo Finance • 8 days ago
Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN™ Rapamycin for Cutaneous Venous Malformations
Yahoo Finance • 20 days ago
Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. as Chief Innovation Officer
Yahoo Finance • 21 days ago
Is Bio-Rad Laboratories (BIO) Entering a Period of More Sustained Recovery?
About
CEO | Mr. Wesley H. Kaupinen |
CFO | Mr. Matthew E. Korenberg |
Address | 125 Strafford Avenue, Wayne, PA, United States, 19087 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 14 |
